AIM:SAR

2 December 2013

Sareum Holdings plc

(“Sareum” or “the Company”)

Sareum Enters Co-Development Agreement in China for Aurora+FLT3 Programme

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that it has signed a co-development agreement with Hebei Medical University Biomedical Engineering Center (“HMUBEC”) to advance its Aurora+FLT3 cancer programme.

Under the terms of the agreement HMUBEC has been granted exclusive rights to carry out pre-clinical and clinical studies within Greater China* to obtain approval for sales in that territory.  Sareum will receive a significant milestone payment once a product receives authorisation for marketing, and up to 15% of operating profit from sales generated in Greater China.

HMUBEC will be required to disclose and exclusively licence to Sareum all pre-clinical and clinical data it generates in the course of the development collaboration in order to facilitate Sareum's own development and commercialisation activities.  This would include conducting any further studies required for authorisation for clinical trials in the rest of the world as well as out-licensing and supporting applications for marketing authorisations outside Greater China.  HMUBEC will be entitled to receive up to 10% of operating profit Sareum receives from any licence agreement or sales made outside Greater China, dependent on the stage at which Sareum out-licences data generated by HMUBEC to a third party.

HMUBEC is an independent research centre operating within Hebei Medical University Science & Technology General Company (HMUSTGC).  Its capabilities include GLP† compliant laboratories, CGMP†† compliant manufacturing capabilities and well-established sales distribution channels in Greater China.  HMUSTGC has successfully developed more than 85 therapeutic products and medical devices for the Chinese market since its formation in 1992. 

Aurora+FLT3 kinase inhibitors have the potential to treat acute myeloid leukaemia (AML, the most common form of adult leukaemia) and various other forms of cancer.  Aurora kinase is involved in the control of mitosis (cell division), and FLT3 kinase over-activation is the most common mutation in AML.  The pre-clinical development candidate that has been licenced by Sareum to HMUBEC has showed particular promise against a range of haematological cancer models including AML and Acute Lymphoblastic Leukaemia (ALL) with an encouraging early safety profile and positive ADME (absorption, distribution, metabolism, excretion) properties.

 

Sareum was advised and assisted on this agreement by Cambridge, UK based technology brokerage Link China Pharma Solutions.

Dr. Tim Mitchell, Chief Executive Officer of Sareum Holdings plc, said:

“This agreement provides us with significant additional resource, exposure to a major market and the flexibility to undertake our own independent research utilising HMUBEC’s findings at any point in the development programme.  HMUBEC also has the capability and resources to advance the Aurora+FLT3 programme from pre-clinical all the way through clinical trials and onto the Chinese market. We believe all this provides a good balance of risk and reward for our shareholders and we look forward to working closely with HMUBEC.”

Professor Donggang Liu, Deputy General Manager of the Hebei Medical University Science & Technology General Company, said:  “We have been very impressed with the results of the studies undertaken on Sareum’s Aurora+FLT3 programme so far and we have real confidence in the programme’s potential to develop a world class drug to treat several forms of blood cancer.  HMUBEC has significant resources and expertise to expedite this research programme, and we look forward to commencing work on this very exciting compound.”

*Greater China includes the People’s Republic of China, and the special administrative regions of Hong Kong and Macau, and Taiwan region.

†GLP: Good Laboratory Practise

††CGMP: Chinese Good Manufacturing Practise

Enquiries:

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

Sanlam Securities UK Limited (Nomad)

Simon Clements

020 7628 2200

Hybridan LLP (Broker)

 

Claire Noyce / William Lynne

020 7947 4350 / 4361

The Communications Portfolio (Media enquiries)

 

Ariane Comstive

+44 (0) 20 7536 2028

ariane.comstive@communications-portfolio.co.uk

 

About Sareum Holdings plc

Sareum is a drug discovery and development company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and autoimmune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum operates an outsourced research model, working with collaborators (SRI International, the CRT Pioneer Fund and Hebei Medical University Biomedical Engineering Center) and a world-wide network of research providers.  Its research pipeline includes two programmes undergoing pre-clinical IND-enabling studies.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL® can also generate drug research programmes against other kinase targets.

For further information, please visit www.sareum.co.uk

About HMUBEC / HMUSTGC

Hebei Medical University Biomedical Engineering Center is an independent research centre operating within Hebei Medical University Science & Technology General Company, which itself forms part of Hebei Medical University (“HMU”).

Through a number of wholly owned subsidiary companies, HMUSTGC currently employs over 570 people developing, manufacturing and distributing its own drugs, as well as some generics .  Since its formation in 1992, HMUSTGC has successfully brought to the Chinese market a total of 15 drugs and more than 60 traditional Chinese medicine products, biologics and medical devices targeting a range of therapeutic areas including cancer, osteoporosis, cardiovascular, digestive, endocrine, respiratory and ocular.

HMU, located in Shijiazhuang (the provincial capital of Hebei Province in the North China Plain), is a comprehensive medical university teaching western medicine, traditional Chinese medicine, pharmacy and other subjects. The university comprises 14 colleges, over 15,000 students and is affiliated to 6 teaching hospitals.

For more information please visit www.hebmu.edu.cn/Channel.aspx?ChId=38

About Link China Pharma Solutions

Link China Pharma Solutions (“LCPS”) is a UK Cambridge based dedicated technology brokerage and services provider bringing in-depth China industry experience and market knowledge to provide a range of specialist services to promote research co-operation, technology transfer and business collaboration between China and UK/EU life science research institutes, biotech and pharmaceutical companies to maximize the value of research and business alliances.  LCPS brings in-depth industry experience and global market knowledge to support UK/EU small, medium and large biopharmaceutical and life science companies to build the collaboration with Chinese partners and provide a full suite of services from strategy alignment, partnership selection, collaborative partnering, outsourcing transaction in drug discovery and development, clinical trial, contract manufacturing, to China market entry and development so that our clients can minimize the cost, gain the competitive advantage in the global market and place themselves well ahead to access one of the fastest growing pharmaceutical markets in the world. www.chinapharma.co.uk .